R1 RCM Inc (RCM) Given Consensus Rating of “Buy” by Brokerages
R1 RCM Inc (NYSE:RCM) has earned an average broker rating score of 2.33 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Brokers have set a 12-month consensus price target of $4.68 for the company and are anticipating that the company will post ($0.02) earnings per share for the current quarter, according to Zacks. Zacks has also assigned R1 RCM an industry rank of 183 out of 265 based on the ratings given to its competitors.
A number of research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of R1 RCM from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 9th. Robert W. Baird restated a “hold” rating and set a $5.00 price target on shares of R1 RCM in a report on Thursday, August 24th.
Institutional investors have recently added to or reduced their stakes in the business. Spark Investment Management LLC raised its holdings in R1 RCM by 195.4% during the 2nd quarter. Spark Investment Management LLC now owns 379,900 shares of the company’s stock worth $1,424,000 after purchasing an additional 251,300 shares during the last quarter. New York State Common Retirement Fund bought a new position in R1 RCM during the 2nd quarter worth approximately $305,000. Nationwide Fund Advisors bought a new position in R1 RCM during the 2nd quarter worth approximately $215,000. SLS Management LLC raised its holdings in R1 RCM by 1.8% during the 2nd quarter. SLS Management LLC now owns 631,210 shares of the company’s stock worth $2,367,000 after purchasing an additional 11,300 shares during the last quarter. Finally, TIAA CREF Investment Management LLC bought a new position in R1 RCM during the 2nd quarter worth approximately $1,014,000.
R1 RCM (NYSE RCM) opened at 3.26 on Friday. The company’s 50-day moving average is $3.27 and its 200-day moving average is $3.77. R1 RCM has a one year low of $1.91 and a one year high of $4.37.
R1 RCM (NYSE:RCM) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.07. The business had revenue of $99.40 million during the quarter, compared to the consensus estimate of $91.95 million. R1 RCM had a negative net margin of 6.74% and a negative return on equity of 51.77%. On average, equities research analysts forecast that R1 RCM will post ($0.04) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “R1 RCM Inc (RCM) Given Consensus Rating of “Buy” by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/09/r1-rcm-inc-rcm-given-consensus-rating-of-buy-by-brokerages.html.
About R1 RCM
R1 RCM Inc, formerly Accretive Health, Inc, is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM Inc and related companies with MarketBeat.com's FREE daily email newsletter.